rss
Arch Dis Child Fetal Neonatal Ed 1999;80:F1-F7 doi:10.1136/fn.80.1.F1
  • Original article

Clinical outcomes of newborn screening for cystic fibrosis

  1. Donna L Watersa,
  2. Bridget Wilckenb,
  3. Les Irwigd,
  4. Peter Van Asperenc,
  5. Craig Mellisc,
  6. Judy M Simpsond,
  7. John Brownc,
  8. Kevin J Gaskina
  1. aJames Fairfax Institute of Paediatric Nutrition Royal Alexandra Hospital for Children, Sydney, PO Box 3515, Parramatta 2124, New South Wales, Australia, bDepartment of Biochemical Genetics, cDepartment of Respiratory Medicine, dDepartment of Public Health, University of Sydney
  1. Professor K J Gaskin.
  • Accepted 11 August 1998

Abstract

AIM To determine how early diagnosis of cystic fibrosis, using neonatal screening, affects long term clinical outcome.

METHODS Fifty seven children with cystic fibrosis born before neonatal screening was introduced (1978 to mid 1981) and a further 60 children born during the first three years of the programme (mid 1981 to 1984), were followed up to the age of 10. The cohorts were compared on measures of clinical outcome, including height, weight, lung function tests, chest x-ray picture and Shwachman score.

RESULTS Age and sex adjusted standard deviation scores (SDS) for height and weight were consistently higher in children screened for cystic fibrosis than in those born before screening. At 10 years of age, average differences in SDS between groups were 0.4 (95% CI −0.1, 0.8) for weight and 0.3 (95% CI −0.1, 0.7) for height. This translates to an average difference of about 2.7 cm in height and 1.7 kg in weight. Mean FEV1 and FVC (as percentage predicted) were significantly higher in the screened cohort at 5 and 10 years of age, with an average difference of 9.4% FEV1(95% CI 0.8, 17.9) and 8.4% FVC (95% CI 1.8, 15.0) at 10 years. Chest x-ray scores were not different between the groups at any age, but by 10 years screened patients scored an average 5.3 (95% CI 1.2, 9.4) points higher on the Shwachman score.

CONCLUSION Although not a randomised trial, this long term observational study indicates that early treatment made possible by neonatal screening may be important in determining subsequent clinical outcomes for children with cystic fibrosis. For countries contemplating the introduction of neonatal screening for cystic fibrosis, its introduction to some areas in a cluster randomised design will permit validation of studies performed to date.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.